his study will test whether giving dexamethasone through a vein can improve pain control after total hip replacement surgery. Dexamethasone is commonly used to reduce nausea and may also help with pain, but it is not clear which dose works best. Patients will be randomly assigned to receive either no dexamethasone, 4 mg, or 8 mg, in addition to standard anesthesia and a nerve block (PENG block). The main goal is to see how long patients go without needing additional pain medication after surgery. The study will also look at pain levels, use of opioid painkillers, nausea and vomiting, blood sugar levels, and possible side effects.
Effective pain control after total hip arthroplasty (THA) remains a key component of perioperative care, as inadequate analgesia may delay mobilization, prolong hospital stay, and increase the need for opioids. Regional anesthesia techniques, such as the pericapsular nerve group (PENG) block, are increasingly used to improve postoperative pain management while preserving motor function. Dexamethasone administered intravenously is commonly used in perioperative care, primarily for the prevention of postoperative nausea and vomiting. In addition, it has been shown to prolong the duration of analgesia when used as an adjunct to regional anesthesia. However, there is still uncertainty regarding the optimal intravenous dose that provides clinically meaningful analgesic benefit without increasing the risk of adverse effects, particularly hyperglycemia. Previous studies have typically used doses ranging from 4 mg to 8 mg, but direct comparisons between these doses, as well as comparison with placebo, remain limited in patients undergoing THA. Furthermore, the potential dose-response relationship of intravenous dexamethasone in this specific surgical population has not been clearly established. This study is designed to address this knowledge gap by evaluating whether intravenous dexamethasone provides additional analgesic benefit in patients undergoing THA with PENG block, and whether higher doses result in improved outcomes compared to lower doses or no dexamethasone. The findings may help optimize perioperative analgesic strategies and support more evidence-based dosing of dexamethasone in orthopedic surgery.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
198
Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 4 mg
Intravenous administration of 0.9% sodium chloride in a volume identical to active treatment, given after induction of anesthesia.
Intravenous dexamethasone administered as a single dose after induction of anesthesia, at doses of 8 mg
Poznan University of Medical Sciences
Poznan, Poland
RECRUITINGTime to First Rescue Analgesia
Time from the end of surgery to the first administration of rescue analgesia (opioid) due to inadequate pain control (Numeric Rating Scale ≥ 4 or patient request).
Time frame: 48 hours after surgery
Postoperative Pain Intensity
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain)
Time frame: 6 hours after surgery
Postoperative Pain Intensity
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain)
Time frame: 12 hours after surgery
Postoperative Pain Intensity
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain)
Time frame: 24 hours after surgery
Postoperative Pain Intensity
Pain intensity at rest assessed using an 11-point Numeric Rating Scale (NRS, 0 = no pain, 10 = worst imaginable pain)
Time frame: 48 hours after surgery
Opioid Consumption
Total opioid consumption converted to morphine milligram equivalents (MME).
Time frame: 48 hours after surgery
Opioid Consumption
Total opioid consumption converted to morphine milligram equivalents (MME).
Time frame: 24 hours after surgery
Incidence of Postoperative Nausea and Vomiting (PONV)
Occurrence of nausea and/or vomiting and need for antiemetic treatment.
Time frame: 24 hours after surgery
Blood Glucose Levels
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone.
Time frame: immidietly after surgery (0 hours after surgery)
Blood Glucose Levels
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone.
Time frame: 6 hours after surgery
Blood Glucose Levels
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone.
Time frame: 12 hours after surgery
Blood Glucose Levels
Perioperative blood glucose measurements to assess the metabolic effect of dexamethasone.
Time frame: 24 hours after surgery
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.